Reproducibility of genetic risk factors identified for long COVID using combinatorial analysis across US and UK patient cohorts with diverse ancestries
Related Experiment Video
Updated: May 15, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
J Sardell1, M Pearson1, K Chocian1
1PrecisionLife Ltd., Unit 8b Bankside, Hanborough Business Park, Long Hanborough, OX29 8LJ, UK.
Insights
This study validates previous long COVID genetic findings in a diverse population, identifying reproducible disease signatures and supporting genetic factors in susceptibility. These results advance precision medicine for long COVID diagnosis and treatment.
Area of Science:
- Genetics
- Genomics
- Epidemiology
Background:
- Long COVID presents a significant global health challenge with complex, debilitating symptoms affecting millions.
- Traditional Genome-Wide Association Studies (GWAS) have yielded limited, non-replicable genetic associations for Long COVID.
- Previous combinatorial analysis identified 73 genes associated with Long COVID in a European ancestry cohort.
Purpose of the Study:
- To assess the reproducibility of Long COVID disease signatures in the ancestrally diverse All of Us (AoU) population.
- To validate findings from a prior combinatorial analysis study in a new cohort.
- To identify genetic associations with Long COVID across diverse ancestral groups.
Main Methods:
- Assessed reproducibility of 5343 Long COVID disease signatures from the Sano GOLD study in the AoU cohort.
- Controlled for population substructure to enhance statistical power for replication.
- Tested for statistically significant enrichment of Sano GOLD signatures positively correlated with Long COVID in AoU.
Main Results:
- Observed significant enrichment (77-83%) of Long COVID-associated signatures in AoU, encompassing 92% of genes from the original study.
- Found at least five disease signatures individually associated with increased Long COVID prevalence in AoU.
- Reproducibility was observed across White, Black/African-American, and Hispanic/Latino cohorts, with strongest rates in self-identified White patients.
Conclusions:
- Demonstrated broad validation of Long COVID disease signals identified by combinatorial analysis, supporting genetic factors in susceptibility.
- Provided evidence for a wider range of genetic associations than previously found by GWAS, supporting precision medicine approaches.
- Achieved the first reproduction of Long COVID genetic associations across diverse populations, promoting health equity and guiding therapeutic development.
Background:
Long COVID is a major public health burden causing a diverse array of debilitating symptoms in tens of millions of patients globally. In spite of this overwhelming disease prevalence, staggering cost, severe impact on patients' lives and intense global research efforts, study of the disease has proved challenging due to its complexity. Genome-wide association studies (GWAS) have identified only four loci potentially associated with the disease, although these results did not statistically replicate between studies. A previous combinatorial analysis study identified a total of 73 genes that were highly associated with two long COVID cohorts in the predominantly (> 91%) white European ancestry Sano GOLD population, and we sought to reproduce these findings in the independent and ancestrally more diverse All of Us (AoU) population.
Methods:
We assessed the reproducibility of the 5343 long COVID disease signatures from the original study in the AoU population. Because the very small population sizes provide very limited power to replicate findings, we initially tested whether we observed a statistically significant enrichment of the Sano GOLD disease signatures that are also positively correlated with long COVID in the AoU cohort after controlling for population substructure.
Results:
For the Sano GOLD disease signatures that have a case frequency greater than 5% in AoU, we consistently observed a significant enrichment (77-83%, p < 0.01) of signatures that are also positively associated with long COVID in the AoU cohort. These encompassed 92% of the genes identified in the original study. At least five of the disease signatures found in Sano GOLD were also shown to be individually significantly associated with increased long COVID prevalence in the AoU population. Rates of signature reproducibility are strongest among self-identified white patients, but we also observe significant enrichment of reproducing disease associations in self-identified black/African-American and Hispanic/Latino cohorts. Signatures associated with 11 out of the 13 drug repurposing candidates identified in the original Sano GOLD study were reproduced in this study.
Conclusion:
These results demonstrate the reproducibility of long COVID disease signal found by combinatorial analysis, broadly validating the results of the original analysis. They provide compelling evidence for a much broader array of genetic associations with long COVID than previously identified through traditional GWAS studies. This strongly supports the hypothesis that genetic factors play a critical role in determining an individual's susceptibility to long COVID following recovery from acute SARS-CoV-2 infection. It also lends weight to the drug repurposing candidates identified in the original analysis. Together these results may help to stimulate much needed new precision medicine approaches to more effectively diagnose and treat the disease. This is also the first reproduction of long COVID genetic associations across multiple populations with substantially different ancestry distributions. Given the high reproducibility rate across diverse populations, these findings may have broader clinical application and promote better health equity. We hope that this will provide confidence to explore some of these mechanisms and drug targets and help advance research into novel ways to diagnose the disease and accelerate the discovery and selection of better therapeutic options, both in the form of newly discovered drugs and/or the immediate prioritization of coordinated investigations into the efficacy of repurposed drug candidates.
More Related Videos
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
Published on: August 21, 2016
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Single Nucleotide Polymorphisms-SNPs
Genomics
Pleiotropy
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...